The Application dimension of the Medical Device Efficacy Testing Service market delineates demand by therapeutic area, reflecting regulatory scrutiny and clinical risk profiles. Cardiovascular devices, encompassing stents and heart valves, command the largest share due to stringent safety standards, driving roughly 30 % of testing revenue. Orthopedic implants, such as joint prostheses, follow with an estimated 25 % share, where mechanical fatigue and biocompatibility testing dominate. Diagnostic imaging equipment, including MRI and CT systems, accounts for about 20 % of the market, emphasizing performance validation and radiation safety. Neurological devices, like deep‑brain stimulators, represent 15 % of the total, with efficacy testing focused on signal fidelity and long‑term tissue response. Smaller niches—Dental devices (5 %) and Other categories (5 %)—contribute modestly but exhibit higher growth potential as personalized and emerging technologies mature. This granular view of Medical Device Efficacy Testing Service segmentation clarifies how each application segment underpins overall market size and informs resource allocation for testing service providers.